Noetic Fund

Numinus is a Vancouver-based company founded in 2019 by Payton Nyquvest and Stacey Wallin, specializing in psychedelic-centered therapeutic products and services. It integrates holistic healthcare approaches with neuro-technology to enhance patient care. Numinus operates a network of clinics, including Numinus Health, Mindspace Services, and the Neurology Center of Toronto, offering a range of services such as ketamine-assisted psychotherapy for conditions like depression, as well as neurological care and counseling by registered psychologists. The company is structured into several operational segments, including clinical research, its Canadian and US clinic networks, and corporate functions, with the majority of its revenue generated from the US segment. Through its laboratory and research and development initiatives, Numinus aims to advance the field of psychedelic therapy and improve mental health outcomes.

Diamond Therapeutics is a Toronto-based company dedicated to developing innovative therapies for mental health conditions through the potential of psychedelic compounds. The company focuses on creating sub-perceptual, non-hallucinogenic treatments, which are designed to be safe and suitable for at-home use. By concentrating on these treatments, Diamond Therapeutics aims to address a wide range of neuropsychiatric conditions, seeking to enhance the effectiveness of existing therapies and promote faster recovery for patients. The company's mission aligns with the urgent need to improve mental health care, aiming to deliver significant benefits to a diverse patient population and contribute meaningfully to the global mental health crisis.

Damona Pharmaceuticals is a pre-clinical biotechnology company focused on developing treatments for cognitive deficits associated with various brain disorders and aging. The company aims to create small molecule therapeutics that address cognitive symptoms and improve normal life functions, particularly for underserved and understudied populations in mental health and aging. By leveraging its innovative research platform, Damona Pharmaceuticals seeks to offer solutions that not only treat but potentially reverse cognitive impairments, addressing previously unresolvable symptoms and enhancing the quality of life for affected individuals.

Bloom operates in two primary sectors: fashion and baby products. The company offers a platform that sells original brand outlets from curated international brands, allowing customers to try on clothing at home before making a purchase. This service includes easy returns for items that do not meet expectations. Additionally, Bloom manufactures a range of elegant baby gear and furniture, including highchairs, cribs, bassinets, and eco-friendly products. The company's diverse offerings cater to the needs of families and individuals seeking quality and convenience in both fashion and baby essentials.

Apollo Neuroscience, Inc. is a company based in Pittsburgh, Pennsylvania, founded in 2016. It manufactures a wearable wellness device designed to assist the body in recovering from chronic stress through gentle vibrations. The company also develops a complementary application that leverages neuroscience and machine learning to enhance heart rate variability and support various wellness activities, including waking up, focusing, unwinding, and improving parasympathetic nervous system function. Apollo's products are sold online and are clinically validated, though they are not intended to treat psychiatric disorders or serve as a substitute for professional medical care.

Psygen specializes in the manufacture of pharmaceutical-grade psychedelic drug products aimed at clinical research and therapeutic applications. The company focuses on creating high-quality psychedelic substances that support healthcare researchers in accelerating the research and development of these innovative drugs. By ensuring that the transformative potential of psychedelics is well understood and accessible, Psygen contributes to advancing the field of psychedelic therapy and enhancing treatment options for various mental health conditions.

Terran Biosciences Inc. is a biotechnology company focused on developing innovative solutions for neurological and mental health disorders. Established in 2017 and headquartered in New York, the company offers a diverse range of products, including a therapeutics pipeline, a medical device program, and a precision medicine platform. Terran Biosciences aims to create impactful therapies and technologies that can significantly improve the quality of life for patients suffering from neurological and psychiatric conditions.

Tactogen is a biopharma startup based in Palo Alto, California, founded in 2020 by neuroscientist Matthew Baggott and entrepreneur Luke Pustejovsky. The company focuses on developing empathogen medicines, which are designed to promote mental wellness and facilitate emotional connection among individuals. Tactogen's innovative approach centers on creating safer and more effective pharmaceuticals, including novel molecules and drug discovery methods aimed at producing unique emotional states that balance openness and motivation. This research-driven initiative seeks to enhance the efficacy of psychotherapy and other psychological treatments while ensuring that empathogens can be prescribed safely for take-home use.

Wake Network, Inc. is a Toronto-based company that specializes in clinical research and the use of fungi and plant-based medicine to promote healing benefits for the mind and body. Established in June 2018, the company has developed a gold-standard regenerative feedback loop that enables it to conduct research and monitor clinical studies on an individualized basis. By integrating the expertise of wellness professionals and leveraging technology, Wake Network aims to advance the future of mental and holistic health through innovative therapeutic solutions.

CaaMTech, Inc. is a drug discovery and optimization company based in Issaquah, Washington, established in 2019. The company specializes in engineering psychedelic drugs, focusing on the creation and optimization of psychedelic compounds and formulations. CaaMTech employs rigorous scientific methods and continuous innovation to develop drugs that meet modern medical standards. Its work aims to enhance health and well-being by addressing various conditions, including depression and PTSD, through the provision of safe and effective psychedelic medicines. Additionally, CaaMTech offers drug safety and efficacy screening services to support its mission in the health industry.

Sana Health, Inc. is a digital health company specializing in a bio-therapeutic device aimed at fostering relaxation to alleviate pain and tension. The company has developed a non-addictive mask and headphone system that employs audio-visual stimulation to enhance the balance between the brain's left and right hemispheres, facilitating a deep state of meditation. This innovative device uses coordinated pulses of light and sound to guide users into a restorative state, thereby improving mental well-being and addressing chronic pain and insomnia. In addition to the hardware, Sana Health offers a mobile application available on both the App Store and Google Play, allowing users to access its features conveniently. Founded in 2015 and headquartered in Lafayette, Colorado, with an additional office in Mill Valley, California, Sana Health is involved in pivotal studies concerning its technology's applications for conditions such as fibromyalgia and neuropathic pain, as well as trials focusing on anxiety and PTSD.

Merlyn Mind is a technology company based in New York that specializes in AI-based solutions tailored for the education sector. Founded in 2018, the company has developed Merlyn, an AI-powered digital assistant designed to enhance teaching and learning experiences. This assistant allows teachers to control multimedia applications in their classrooms through natural voice commands and remote control, facilitating a more intuitive interaction with technology. By minimizing the effort required to leverage digital tools, Merlyn Mind empowers educators to focus on delivering effective instruction while seamlessly integrating technology into their teaching practices.

Apollo Neuroscience, Inc. is a company based in Pittsburgh, Pennsylvania, founded in 2016. It manufactures a wearable wellness device designed to assist the body in recovering from chronic stress through gentle vibrations. The company also develops a complementary application that leverages neuroscience and machine learning to enhance heart rate variability and support various wellness activities, including waking up, focusing, unwinding, and improving parasympathetic nervous system function. Apollo's products are sold online and are clinically validated, though they are not intended to treat psychiatric disorders or serve as a substitute for professional medical care.

Woven Science is a life sciences platform focused on creating a comprehensive solution for mental healthcare, particularly through psychedelic therapeutics. The company aims to establish one of the first vertically integrated patient care systems in this field, encompassing all stages from drug development to clinic distribution. Woven Science emphasizes a model of mutuality, balancing purpose and profit, and is notable for its commitment to social responsibility by allocating 10% of its realized profits to nonprofits dedicated to supporting indigenous culture and ecosystem preservation. By building, backing, and incubating innovative companies within its ecosystem, Woven Science seeks to address the mental illness epidemic with a focus on delivering scalable and effective mental health outcomes throughout the treatment process.

Gilgamesh Pharmaceuticals, Inc. is a preclinical biotechnology company based in New York that specializes in developing novel psychotropic drugs aimed at treating mental illnesses. Established in 2019, the company focuses on creating innovative compounds that enhance the therapeutic benefits of classic psychedelics while improving safety, tolerability, duration, and efficacy. Gilgamesh addresses the growing global mental health crisis by providing treatments for various neuropsychiatric conditions, including depression, anxiety, substance use disorders, and stress-related issues. Through a combination of medicinal chemistry and drug development expertise, the company aims to accelerate the availability of effective therapies, ultimately improving the quality of life for individuals suffering from central nervous system disorders.

Bexson Biomedical is focused on creating an innovative formulation of ketamine specifically designed for the treatment of chronic and acute pain disorders. The company is developing a subcutaneous ketamine delivery system that aims to overcome the limitations of existing ketamine preparations, particularly in terms of controlling overdosing and minimizing the need for patient monitoring. Their lead product features a unique formulation of ketamine that is administered through a minimally invasive, wearable, subcutaneous infusion pump. This approach enables healthcare providers to more effectively manage pain in patients, enhancing treatment outcomes while addressing safety concerns associated with traditional ketamine therapies.

People Science is a technology-driven research and development platform focused on alternative medicine. The company facilitates connections between health-conscious individuals, medical professionals, and research scientists while supporting manufacturers in creating products grounded in scientific testing. By providing a scaled research platform, People Science enables customers to identify alternative medicines that may aid in their wellness journeys, ensuring that these solutions are backed by rigorous research and evidence.

Frequency Breathwork is a fitness platform focused on emotional well-being through breathwork. It offers live-streamed virtual classes, training sessions, and events designed to help individuals manage anxiety and depression, improve sleep, and enhance energy and clarity. The platform aims to enable users to optimize their body functions and awaken higher states of consciousness, promoting a sense of calm and connection. By engaging in breathwork, clients are guided to tune into their personal frequency and unlock their full potential.

Beckley Psytech Limited is a company based in Oxford, United Kingdom, that specializes in developing psychedelic drugs aimed at treating psychiatric and neurological diseases. Founded in 2014, the company explores the therapeutic potential of substances such as psilocybin to address mental health issues, including depression and other debilitating neuropsychiatric conditions. Beckley Psytech is focused on integrating clinically validated psychedelic medicines into contemporary medical practices, providing alternative treatments for patients who have significant unmet needs. Through its drug pipeline, the company aims to innovate and differentiate its offerings in the marketplace, enhancing options for individuals suffering from these disorders.

The Alexander Shulgin Research Institute (ASRI) is a research organization focused on the discovery and development of psychedelic substances for therapeutic applications. It aims to identify new compounds that produce psychedelic experiences in healthy individuals and to create effective delivery systems for these substances. By emphasizing the design, chemical synthesis, and pharmacological evaluation of novel compounds, ASRI seeks to contribute to advancements in the healthcare industry. Additionally, the institute is committed to educational initiatives surrounding psychedelics, enhancing understanding and awareness of their potential benefits in medicinal contexts.

Eleusis is a clinical stage life science company focused on developing psychedelic drug therapies aimed at addressing unmet medical needs in psychiatry and beyond. The company is dedicated to unlocking the therapeutic potential of serotonin 2A receptor agonists, commonly known as psychedelics, while managing their psychoactive effects. Eleusis is working on a novel approach to transform psilocybin into a safe, effective, convenient, and affordable treatment option for depression. This innovation seeks to provide healthcare providers and pharmaceutical companies with alternative solutions that can meet a wide range of patient needs that are not adequately addressed by traditional therapies.

Cybin is a biopharmaceutical company dedicated to advancing research and development in psychedelic and medicinal mushrooms. It focuses on creating safe and effective therapeutics for mental health issues, with an emphasis on psilocybin-based products. The company is actively launching these products in jurisdictions where they are permitted and is engaged in clinical studies across North America and other regions. Through strategic partnerships with academic and institutional entities, Cybin seeks to develop novel compounds and delivery mechanisms, aiming to provide innovative treatments for various psychiatric and neurological conditions.

COMPASS Pathways is a mental health care company based in Cheshire, United Kingdom, with operations in the United States. The company is focused on developing innovative therapies for treatment-resistant depression (TRD) using its proprietary psilocybin formulation, COMP360. Currently undergoing Phase IIb clinical trials, COMP360 aims to provide a new treatment option for patients who have not responded to traditional depression therapies. COMPASS Pathways emphasizes the combination of psilocybin-assisted therapy with psychological support to enhance treatment efficacy. The company is committed to addressing the significant unmet needs in mental health care by advancing evidence-based solutions for those suffering from mental health challenges.

Eve Health Systems is a data-driven health platform that helps patients to connect with their clinicians.